Dr. Christina S. Baik
Claim this profileFred Hutchinson Cancer Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
12 reported clinical trials
19 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR positive
2Lung Cancer
Stage IV
Stage III
EGFR positive
Affiliated Hospitals
Clinical Trials Christina S. Baik is currently running
Osimertinib
for Non-Small Cell Lung Cancer
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 242 criteria
NVL-330
for Advanced Lung Cancer
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced or metastatic HER2-altered NSCLC. Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL-330 in patients with advanced or metastatic HER2 mutant NSCLC.
Recruiting1 award Phase 12 criteria
More about Christina S. Baik
Clinical Trial Related6 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Christina S. Baik has experience with
- Pembrolizumab
- Osimertinib
- Ramucirumab
- SX-682
- Repotrectinib (TPX-0005)
- Tarloxotinib Bromide
Breakdown of trials Christina S. Baik has run
Non-Small Cell Lung Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christina S. Baik specialize in?
Christina S. Baik focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Christina S. Baik currently recruiting for clinical trials?
Yes, Christina S. Baik is currently recruiting for 7 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Christina S. Baik has studied deeply?
Yes, Christina S. Baik has studied treatments such as Pembrolizumab, Osimertinib, Ramucirumab.
What is the best way to schedule an appointment with Christina S. Baik?
Apply for one of the trials that Christina S. Baik is conducting.
What is the office address of Christina S. Baik?
The office of Christina S. Baik is located at: Fred Hutchinson Cancer Center, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutchinson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.